Gastrointestinal Stromal Tumor (GIST) Market Spotlight Report 2021: 10-year Disease Incidence and Prevalence Forecasts, Probability of Success, Licensing and Asset Acquisition Deals, Revenue Forecasts - ResearchAndMarkets.com
The "Market Spotlight: Gastrointestinal Stromal Tumor (GIST)" report has been added to ResearchAndMarkets.com's offering.
- The "Market Spotlight: Gastrointestinal Stromal Tumor (GIST)" report has been added to ResearchAndMarkets.com's offering.
- This Market Spotlight report covers the Gastrointestinal Stromal Tumor (GIST) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, regulatory events, probability of success, a 10-year disease incidence forecast, and drug-specific revenue forecasts.
- The publisher estimates that in 2019, there were 100,200 incident cases of gastrointestinal stromal tumor (GIST) worldwide, and expects that number to increase to 109,000 incident cases by 2028.
- Novartis leads industry sponsors with by far the highest overall number of clinical trials for GIST.